ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

ProQR Therapeutics N.V.NASDAQ: PRQR

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of €13.6M (cash outflow) rose 35.0% year over year, behind the +51.2% change in trailing-twelve-month net income. Sequentially, it rose 53.9% from the prior quarter. Over 3 fiscal years it compounded at -14.2% a year.

Context

  • Net income amounted to 265.2% of revenue in FY2025, up 118.4 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -€46.65M (+15.1%) for the fiscal year ending Dec 2026, a slowdown from the +45.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€13.6M+53.9% QoQ
Last fiscal yearDec 2025
-€40.52M+45.9% YoY
LTMMar 2026
-€45.62M+51.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.0%+2.8%-32.1 pp
1 year+45.9%+15.1%-30.8 pp
3-year CAGR-14.2%+17.0%+31.2 pp
5-year CAGR-9.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
(40.52M) EUR
Year-over-year change
-45.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +51.2% is the 3rd highest of 11, against a peer median of +14.0%.
  • Net income amounts to 339.4% of revenue for PRQR, versus a peer median of 749.8%.
PRQR Competitors
Net Income for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$80.71B USD+146477.0%+53.5%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$239.55M USD+441.4%—110.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M USD-31.1%-16.9%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$166.12M USD-770.3%+15.0%2895.1%
EDITEditas Medicine, Inc.LTM Mar 2026$108.95M USD-56.6%-10.1%281.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M USD+15.4%—173.5%
ZURAZura Bio LimitedLTM Mar 2026$77.43M USD+24.7%+35.9%—
IMMPImmutep LimitedFY2025A$61.43M AUD+43.8%+24.0%1218.0%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$51.99M USD+12.6%+8.9%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€45.62M EUR+51.2%-14.2%339.4%
MREOMereo BioPharma Group plcLTM Mar 2026$35.71M USD-24.3%-0.3%7142.0%
Peer median (excluding PRQR) —+14.0%+11.9%749.8%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(60.8M)(64.2M)(27.74M)(27.76M)(40.52M)
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
Deferred Income Tax117K96K(78K)(197K)0
Stock-Based Compensation6.22M2.87M3.11M2.54M0
Change in Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Other Non-Cash Items1.11M(4.8M)(5.21M)(474K)3.94M
Operating Cash Flow(26.01M)(68.51M)21.55M(36.39M)(50.71M)
Capital Expenditures(484K)(708K)(1.37M)(1.42M)(979.75K)
Acquisitions (Net)00000
Purchases of Investments000(17M)0
Sales of Investments00017M0
Other Investing Activities59K6K5.65M(2.66M)0
Investing Cash Flow(425K)(702K)4.28M(4.07M)(979.74K)
Debt Repayment26.84M(45.05M)(2.63M)(1.58M)(1.91M)
Common Stock Issued108.48M14.12M071.64M66.28K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.52M34K354K223K75.19K
Financing Cash Flow136.83M(30.89M)(2.28M)70.28M(1.76M)
Effect of Forex Changes1.29M7.35M599K673K14.15M
Net Change in Cash111.69M(92.75M)24.15M30.48M(39.3M)
Free Cash Flow(26.5M)(69.22M)20.18M(37.81M)(51.69M)

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.